riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system + placebo: 0.0% riboflavin ophthalmic solution with the KXL system
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Corneal Ectasia
Conditions
Corneal Ectasia
Trial Timeline
Jul 1, 2012 → —
NCT ID
NCT01643252About riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system + placebo: 0.0% riboflavin ophthalmic solution with the KXL system
riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system + placebo: 0.0% riboflavin ophthalmic solution with the KXL system is a phase 3 stage product being developed by Glaukos for Corneal Ectasia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01643252. Target conditions include Corneal Ectasia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01643252 | Phase 3 | Withdrawn |
Competing Products
12 competing products in Corneal Ectasia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution | Santen Pharmaceutical | Phase 2 | 52 |
| Vehicle Ophthalmic Solution + Omaveloxolone Ophthalmic Suspension 0.5% + Omaveloxolone Ophthalmic Suspension 1% | AbbVie | Phase 2 | 52 |
| 0.3% hypromellose | Novartis | Approved | 85 |
| Mycophenolate Mofetil 2x 1g | Roche | Approved | 85 |
| Subconjunctival aflibercept | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen) | Glaukos | Phase 2 | 49 |
| lufepirsen high dose + Vehicle + lufepirsen low dose | Glaukos | Phase 2 | 49 |
| OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + Placebo | Oculis Holding AG | Phase 2 | 47 |
| DT-168 | Design Therapeutics | Phase 2 | 47 |
| KPI-012 + KPI-012 Vehicle | Kala Pharmaceuticals | Phase 2 | 44 |
| loteprednol etabonate 0.25% ophthalmic suspension | Kala Pharmaceuticals | Approved | 77 |
| QR-504a | ProQR | Phase 1 | 25 |